Joint call for evidence for NHS Net Zero Aseptic/Technical Services Initiatives from NHE England, PASG and Regional Quality Assurance.

Hello!

We are pleased to launch a joint call for evidence for NHS Net Zero Aseptic/Technical Services Initiatives from NHE England, PASG and Regional Quality Assurance.

The NHS has committed to deliver the world’s first net zero health service and respond to climate change, improving health now and for future generations. Aseptic Services teams provide a critical service, ensuring patients receive safe, efficacious prepared injectable medication; but this service is inherently high resource and energy intensive. The pathway to a more sustainable service also aligns with wider initiatives like reduction in waste, cheaper operating costs, and improved staff engagement.

This call for evidence seeks to understand work already being undertaken or planned within the system to reduce the environmental impacts of aseptic services, the level of understanding and engagement in Net Zero and any blockers to progress.

We aim to get good views from across the UK, NHS facilities and from different members from the team so please do cascade widely and to all members of the team.

Please review and respond to the call for evidence on the following link by 09:00 13th November 2023

https://forms.office.com/e/rg5YNi51Tu

Kind Regards,

 

Matt

Matt Greening | Senior Pharmacy Professional Advisor – Infusions and Special Medicines Programme

Hospital Pharmacy Modernisation Team – NHS England

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article